StockNews.com assumed coverage on shares of Mirati Therapeutics (NASDAQ:MRTX – Free Report) in a research report report published on Friday morning. The brokerage issued a sell rating on the biotechnology company’s stock. MRTX has been the subject of a number of other reports. SVB Leerink reiterated a market perform rating and issued a $58.00 price […]